|
Play Video: The Importance of Insider Buying
|
|
|
The table below summarizes the most recent Alexion Pharmaceuticals insider buying information, with links below the price to see the
CAGR achieved by each insider on their purchases. As the saying goes on Wall St., there are many
possible reasons to sell a stock, but only one reason to buy. Watch the importance of insider buying video for more
information about why Alexion Pharmaceuticals insider buys are important for investors to follow.
Date | Insider | Price | Amount |
3-18-2020 Insider Buy |
BROS. Advisors LP Baker Director |
$82.01
CAGR »
|
$6,673,934.61 81,379 shares |
3-18-2020 Insider Buy |
BROS. Advisors LP Baker Director |
$78.33
CAGR »
|
$32,791,129.21 418,621 shares |
4-30-2018 Insider Buy |
Christopher J. Coughlin Director |
$120.79
CAGR »
|
$1,207,900.00 10,000 shares |
6-14-2017 Insider Buy |
Ludwig Hantson CEO |
$116.72
CAGR »
|
$1,167,200.00 10,000 shares |
6-15-2017 Insider Buy |
Christopher J. Coughlin Director |
$117.10
CAGR »
|
$234,200.00 2,000 shares |
6-14-2017 Insider Buy |
BROS. Advisors LP Baker Director |
$116.32
CAGR »
|
$156,915,444.07 1,348,955 shares |
6-15-2017 Insider Buy |
BROS. Advisors LP Baker Director |
$117.33
CAGR »
|
$77,530,746.64 660,779 shares |
6-14-2017 Insider Buy |
BROS. Advisors LP Baker Director |
$116.32
CAGR »
|
$156,915,444.07 1,348,955 shares |
6-15-2017 Insider Buy |
BROS. Advisors LP Baker Director |
$117.33
CAGR »
|
$77,530,746.64 660,779 shares |
12-15-2014 Insider Buy |
David R. Brennan Director |
$186.99
CAGR »
|
$93,495.00 500 shares |
10-17-2014 Insider Buy |
M. Michele Burns Director |
$167.32
CAGR »
|
$1,673.20 10 shares |
3-5-2012 Insider Buy |
Alvin S. Parven Director |
$84.95
CAGR »
|
$11,893.00 140 shares |
Also See: Institutional Holders of ALXN
Also See: SEC filings
Below we present the annualized performance delivered by Alexion Pharmaceuticals stock since 3-18-2020 (the date of the most recent
insider purchase). The performance of the investment from the time Alexion Pharmaceuticals insider buying occurred is the ultimate
test of whether insiders were right about ALXN being a good buy.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
03/19/2020 |
|
End date: |
07/21/2021 |
|
Start price/share: |
$83.50 |
|
End price/share: |
$182.50 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
118.56% |
|
Average Annual Total Return: |
79.25% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$21,855.76 |
|
Years: |
1.34 |
|
Alexion Pharmaceuticals Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.),
and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these
categories, but instead file their holdings quarterly on the latest form 13F filings.
While recent Alexion Pharmaceuticals insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding ALXN
|
|